Martin Capital Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.54M | Sell |
188,551
-322
| -0.2% | -$8.42K | 1.67% | 33 |
|
|
2026
Q1 | $5.3M | Buy |
188,873
+769
| +0.4% | +$20.5K | 1.97% | 29 |
|
|
2025
Q4 | $4.68M | Buy |
188,104
+1,297
| +0.7% | +$32.7K | 1.76% | 31 |
|
|
2025
Q3 | $4.76M | Sell |
186,807
-3,766
| -2% | -$93K | 1.85% | 32 |
|
|
2025
Q2 | $4.62M | Buy |
190,573
+135,344
| +245% | +$3.16M | 1.81% | 29 |
|
|
2025
Q1 | $1.4M | Buy |
55,229
+551
| +1% | +$14.4K | 1.67% | 33 |
|
|
2024
Q4 | $1.45M | Sell |
54,678
-82,008
| -60% | -$2.22M | 1.72% | 31 |
|
|
2024
Q3 | $3.96M | Sell |
136,686
-44,438
| -25% | -$1.3M | 1.95% | 27 |
|
|
2024
Q2 | $5.07M | Buy |
181,124
+843
| +0.5% | +$23.2K | 2.05% | 26 |
|
|
2024
Q1 | $5M | Buy |
180,281
+96,699
| +116% | +$2.68M | 1.92% | 30 |
|
|
2023
Q4 | $2.41M | Sell |
83,582
-18,892
| -18% | -$571K | 0.98% | 40 |
|
|
2023
Q3 | $3.4M | Buy |
102,474
+2,965
| +3% | +$105K | 1.43% | 38 |
|
|
2023
Q2 | $3.65M | Sell |
99,509
-720
| -0.7% | -$28K | 1.48% | 38 |
|
|
2023
Q1 | $4.09M | Sell |
100,229
-65,251
| -39% | -$2.82M | 1.7% | 34 |
|
|
2022
Q4 | $8.48M | Sell |
165,480
-11,437
| -6% | -$548K | 3.5% | 1 |
|
|
2022
Q3 | $7.74M | Buy |
176,917
+36,218
| +26% | +$1.76M | 3.59% | 1 |
|
|
2022
Q2 | $7.38M | Buy |
140,699
+6,788
| +5% | +$346K | 3.5% | 1 |
|
|
2022
Q1 | $6.93M | Sell |
133,911
-50,070
| -27% | -$2.6M | 3.17% | 2 |
|
|
2021
Q4 | $10.9M | Buy |
183,981
+297
| +0.2% | +$14.7K | 5.13% | 1 |
|
|
2021
Q3 | $7.9M | Buy |
183,684
+4,376
| +2% | +$194K | 3.99% | 1 |
|
|
2021
Q2 | $7.02M | Buy |
179,308
+2,050
| +1% | +$79.7K | 3.56% | 2 |
|
|
2021
Q1 | $6.42M | Buy |
177,258
+7,814
| +5% | +$277K | 3.41% | 2 |
|
|
2020
Q4 | $6.24M | Sell |
169,444
-11,651
| -6% | -$427K | 3.64% | 2 |
|
|
2020
Q3 | $6.31M | Sell |
181,095
-3,767
| -2% | -$132K | 4.22% | 2 |
|
|
2020
Q2 | $5.74M | Sell |
184,862
-2,928
| -2% | -$99.5K | 4.03% | 1 |
|
|
2020
Q1 | $5.82M | Sell |
187,790
-4,912
| -3% | -$167K | 4.43% | 1 |
|
|
2019
Q4 | $7.16M | Buy |
192,702
+11,174
| +6% | +$398K | 4.23% | 1 |
|
|
2019
Q3 | $6.19M | Buy |
181,528
+30,336
| +20% | +$1.1M | 4.16% | 1 |
|
|
2019
Q2 | $6.21M | Buy |
151,192
+6,145
| +4% | +$244K | 4.4% | 1 |
|
|
2019
Q1 | $5.84M | Buy |
145,047
+16,474
| +13% | +$660K | 4.51% | 1 |
|
|
2018
Q4 | $5.33M | Buy |
128,573
+5,404
| +4% | +$224K | 4.91% | 1 |
|
|
2018
Q3 | $5.15M | Buy |
123,169
+2,804
| +2% | +$108K | 4.61% | 1 |
|
|
2018
Q2 | $4.14M | Sell |
120,365
-6,069
| -5% | -$207K | 4.23% | 1 |
|
|
2018
Q1 | $4.26M | Buy |
126,434
+3,620
| +3% | +$124K | 4.24% | 2 |
|
|
2017
Q4 | $4.22M | Buy |
+122,814
| New | +$4.19M | 4.38% | 3 |
|
Other funds holding PFE
CWP
ORIO
CNB
KC
WAM
P
Martin Capital Partners's PFE Position: Q2 2026 in Review
Martin Capital Partners reduced its Pfizer (PFE) stake by 0.17% in Q2 2026, selling an estimated $8.42K and leaving 188,551 shares worth $4.54M. The position accounts for 1.67% of the portfolio, ranked #33.
Martin Capital Partners first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $10.9M in Q4 2021. 446 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Martin Capital Partners held 188,551 shares of Pfizer worth $4.54M as of Q2 2026.
- Martin Capital Partners sold 322 Pfizer shares in Q2 2026, an estimated $8.42K.
- Pfizer made up 1.67% of Martin Capital Partners's portfolio in Q2 2026, its #33 holding.
- Martin Capital Partners first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Martin Capital Partners's Pfizer position peaked at $10.9M in Q4 2021.
- 446 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Martin Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.